Molecular Testing for Thyroid Nodules: Past, Present & Future with Dr. Raghunathan

Published 2024-04-26
We are honored to have Dr. Rajam Raghunathan present "Molecular Testing for Indeterminate Thyroid Nodules Past, Present & Future." Dr. Kepal Patel joins as the featured expert discussant.

0:00 Webinar

2:15 Dr. Raghunathan presents

5:00 Molecular Testing Utility
Dr. Raghunathan explains molecular diagnostics as crucial for managing indeterminate cytology cases, such as Bethesda III and IV. These diagnostics guide treatment for 30% of U.S. FNA biopsies, reducing unnecessary surgeries and related costs by managing over 90% of benign cases nonoperatively.

8:00 Types & Utility of Molecular Testing
Dr. Raghunathan discusses the selection and clinical impact of various molecular tests, stressing their role in pre-operative risk assessment despite histology remaining the definitive standard.

25:22 Dr. Patel presents

32:00 Appropriateness of Molecular Testing
Dr. Patel considers molecular testing valuable primarily as a pre-operative adjunct to refine cancer risk assessment, particularly when thyroidectomy decisions are uncertain due to ambiguous clinical, imaging, and cytologic features.

42:39 Discussion with Q&A

** Check out our other programs! **

The THANC Guide
thancguide.org/

TIRO: Thyroid Int'l Recommendations Online
tiro.expert/

** Follow us on Twitter! **
@thancfoundation - shorturl.at/puwS0

THANC on FB - shorturl.at/svNY4

All Comments (1)